ROCKVILLE, MD – October 3, 2023 – DP Clinical congratulates NervGen Pharma Corp., a biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, on dosing its first subject in the Company’s landmark Phase 1b/2a clinical trial for its proprietary lead compound, NVG-291, in individuals with spinal cord injury (SCI). Read more at NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury – NervGen Pharma.